Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cabazitaxel (taxoid XRP6258) 是一种紫杉烷类的抗肿瘤剂,可用于治疗多西他赛失败后的去势抵抗性转移性前列腺癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 418 | 现货 | ||
50 mg | ¥ 671 | 现货 | ||
100 mg | ¥ 1,263 | 现货 | ||
500 mg | ¥ 3,798 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 460 | 现货 |
产品描述 | Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. |
体外活性 | 使用SF-295和U251人成胶质细胞瘤细胞系,产生原位和皮下鼠异种移植物. Cabazitaxel治疗导致大部分皮下植入的肿瘤完全消退.Cabazitaxel在其它相关模型中也有明显的抗肿瘤活性.Cabazitaxel在小鼠肿瘤异种移植模型 (结肠 C38 和 胰腺 P03)中,引起完全肿瘤消退.此外,Cabazitaxel在原位模型中导致10个U251肿瘤中的4个完全肿瘤消退. |
体内活性 | Cabazitaxel的平均离体人血浆蛋白结合率为91.6%。Cabazitaxel会被迅速广泛地代谢成多种代谢产物。Cabazitaxel在多个鼠和人的抗性细胞系中都有活性。Cabazitaxel会提高大鼠肝细胞中CYP3A的酶活性。Cabazitaxel在3种结肠癌细胞株(HCT-116,HCT-8和 HT-29) 中显示出高抗肿瘤活性。用相对较低浓度的Cabazitaxel处理四天会产生明显的细胞毒性。 |
细胞实验 | The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells are seeded onto a 96-well plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs and free CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICG and free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different final concentrations. The incubation continued for another 48 hours. 20 μL MTT solutions (5 mg/mL in PBS) are added into each well and cells are incubated for another 4 hours under 37°C. Subsequently the medium is removed and 150 μL dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals. Then the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium are evaluated as controls. |
别名 | XRP6258, 卡巴他塞, RPR-116258A, TXD 258, taxoid XRP6258 |
分子量 | 835.93 |
分子式 | C45H57NO14 |
CAS No. | 183133-96-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (111.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1963 mL | 5.9814 mL | 11.9627 mL | 29.9068 mL |
5 mM | 0.2393 mL | 1.1963 mL | 2.3925 mL | 5.9814 mL | |
10 mM | 0.1196 mL | 0.5981 mL | 1.1963 mL | 2.9907 mL | |
20 mM | 0.0598 mL | 0.2991 mL | 0.5981 mL | 1.4953 mL | |
50 mM | 0.0239 mL | 0.1196 mL | 0.2393 mL | 0.5981 mL | |
100 mM | 0.012 mL | 0.0598 mL | 0.1196 mL | 0.2991 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cabazitaxel 183133-96-2 Autophagy Cytoskeletal Signaling Microtubule Associated Microtubule/Tubulin XRP6258 卡巴他塞 RPR-116258A inhibit taxoid XRP-6258 XRP-6258 XRP 6258 TXD-258 TXD 258 TXD258 taxoid XRP 6258 taxoid XRP6258 Inhibitor inhibitor